Results 51 to 60 of about 132,229 (258)

Immediate Growth Control in Response to Boiling Histotripsy is Prognostic for Intratumoral Immune Activation

Advanced Science, EarlyView.
Boiling Histrotripsy (BH), a mechanical form of focused ultrasound (FUS), allows for non‐invasive and non‐ionizing tissue destruction. Utilizing a BH treatment protocol that yielded bifurcating primary tumor growth responses, we found that immediate BH‐induced tumor growth control identifies tumors with acute reductions in antigen‐presenting cells (APC)
Lydia E. Kitelinger, Matthew R. DeWitt, Carly M. Van Wagoner, Claire A. Conarroe, Charles C. Funk, Aaron B. Streit, AeRyon Kim, Richard J. Price, Timothy N. J. Bullock   +8 more
wiley   +1 more source

O‐GlcNAcylation Regulation of SNAP29‐Dependent Autophagy Activation Dictates Chemoresistance in Gastric Cancer

Advanced Science, EarlyView.
Model illustrating the proposed mechanism by which chemotherapy‐induced downregulation of OGT disrupts SNAP29 O‐GlcNAcylation, promoting STX17‐SNAP29‐VAMP8 SNARE complex assembly and protective autophagy, leading to chemoresistance, which in turn establishes a feedforward loop to perpetuate drug tolerance.
Liang Tang, Shaoji Zhao, Ziling Shao, Tao Luo, Baifu Peng, Yifan Liu, Jinning Ye, Jianjun Peng, Kaiyu Sun, Jianbo Xu   +9 more
wiley   +1 more source

Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non‐Canonical BAF Complex in Colorectal Cancer

Advanced Science, EarlyView.
This study reveals that Tex10 drives oxaliplatin resistance in colorectal cancer by competitively binding BRD9 to disrupt the ncBAF complex, thereby suppressing AMBRA1 transcription and ULK1‐mediated autophagy. Gemcitabine is identified as a direct Tex10 inhibitor that restores autophagy and overcomes resistance.
Ping Xu, Jie Huang, Xiaojin Gao, Lin Deng, Yanheng Deng, Denglu Wang, Chunlei Yu, Yunxiang Zhang, Jingdong Li, Xiaocong Xiang   +9 more
wiley   +1 more source

Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy

Cancer Medicine, 2020
Neoadjuvant chemotherapy is the current standard of care for large, advanced, and/or inoperable tumors, including triple‐negative breast cancer. Although the clinical benefits of neoadjuvant chemotherapy have been illustrated through numerous clinical ...
Yanding Zhao, Evelien Schaafsma, Chao Cheng   +2 more
doaj   +1 more source

GM‐CSF Promotes Neutrophil PD‐L1 Expression Through the VEGFR‐2/STAT6/CSF2 Signaling Axis in Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
VEGFR‐2 signaling in OSCC activates Src–STAT6‐dependent CSF2 transcription, driving tumor‐derived GM‐CSF secretion. GM‐CSF programs neutrophils to express PD‐L1 through STAT5–mTOR/S6K signaling, suppressing cytotoxic CD8+ T cells. This pathway reveals a tumor–neutrophil immune checkpoint circuit that limits anti‐PD‐1 responsiveness in OSCC.
Fangxing Zhu, Yuanhe You, Yiyi Zhang, Yibin Dai, Xinyu Zhou, Yong Fu, Xi Lu, Yingying Huang, Zhihang Zhou, Ronghui Xia, Wutong Ju, Zhaoqi Yuan, Laiping Zhong, Tongchao Zhao   +13 more
wiley   +1 more source

Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy

Nature Communications
Platinum-based neoadjuvant chemotherapy prior to radical cystectomy is the preferred treatment for muscle-invasive bladder cancer despite modest survival benefit and significant associated toxicities.
A. Contreras-Sanz, G. L. Negri, M. J. Reike, H. Z. Oo, J. M. Scurll, S. E. Spencer, K. Nielsen, K. Ikeda, G. Wang, C. L. Jackson, S. Gupta, M. E. Roberts, D. M. Berman, R. Seiler, G. B. Morin, P. C. Black   +15 more
doaj   +1 more source

Neoadjuvant chemotherapy for advanced ovarian cancer

International Journal of Gynecology & Obstetrics, 1994
The purpose of this study was to compare the survival of women with clinical, radiologic, and histologic findings compatible with advanced ovarian cancer who were treated with neoadjuvant chemotherapy to that of a group of women with FIGO stage IIIC (suboptimal debulking) and stage IV epithelial ovarian cancers treated with the same chemotherapy ...
P E, Schwartz, J T, Chambers, R, Makuch
openaire   +2 more sources

Nanoparticle‐Mediated TIPE1 mRNA Delivery Enhances Paclitaxel Sensitivity in Triple‐Negative Breast Cancer by Modulating RAB7A Ubiquitination‐Associated Stability and Autophagy

Advanced Science, EarlyView.
TIPE1m NPs nanoparticles restore TIPE1 expression, promote RAB7A ubiquitination and degradation, suppress autophagic flux, and resensitize paclitaxel‐resistant triple‐negative breast cancer to therapy. ABSTRACT Acquired paclitaxel (PTX) resistance remains a major obstacle in triple‐negative breast cancer (TNBC) treatment.
Wei Hu, Qishuai Chen, Yan Ma, Yang Liu, Xianing Dong, Wenjuan Wei, Jianxin Du, Shusheng Qiu, Maojin Tian, Peiqing Zhao   +9 more
wiley   +1 more source

Dynamic Contrast-Enhanced MR Imaging in a Phase Ⅱ Study on Neoadjuvant Chemotherapy Combining Rh-Endostatin with Docetaxel and Epirubicin for Locally Advanced Breast Cancer

International Journal of Medical Sciences, 2013
Background: Anti-angiogenesis is a promising therapeutic strategy for locally advanced breast cancer. We performed this phase II trial to evaluate the anti-angiogenesis and anti-tumor effect of rh-endostatin combined with docetaxel and epirubicin in ...
Qianxin Jia, Junqing Xu, Weifeng Jiang, Minwen Zheng, Mengqi Wei, Jianghao Chen, Ling Wang, Yi Huan
doaj  

Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen, Yangyi Wang, Tingting Li, Changqing Guo, Zhe Xie, Zhixian Zhang, Xinghua Han, Wei Wang, Jian Wang, Xiaopeng Ma, Yuanzeng Min   +10 more
wiley   +1 more source